Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Mouse L-929 cells (L cells), human oligodendroglioma cells, and rat glioma cells were persistently infected with vesicular stomatitis virus (VSV) mutant tsG31 and maintained for at least 4 years at 37 degrees C. The striking observation in this study was that there is a marked difference in neurovirulence among the persistent infections (PIs) derived from the three cell lines. tsG31 VSV derived from persistently infected L cells and oligodendroglioma cells remained highly virulent as assayed by intracerebral (i.c.) inoculation into 3-week-old Swiss mice. In contrast, tsG31 VSV isolated from glioma cells lost neurovirulence by passage 20. Persistently infected glioma cells were carried through more than 180 passages without reemergence of neurovirulent virus. Importantly, glioma PI virus neurovirulence was restored quickly by i.c. passage in mice and more slowly by passage through normal L cells. In contrast, the neurovirulence of L-cell PI virus was enhanced by i.c. passage in mice and slowly reduced by passage through normal glioma cells. Furthermore, no alteration in neurovirulence was observed in the case of oligodendroglioma PI virus. Although the mechanism(s) underlying the loss of virulence in glioma cells is unclear, our studies suggest that either strict temperature sensitivity or the presence of a heat-labile transcriptase or both play a major role in this phenomenon.
 ...
PMID:Persistent infection of a temperature-sensitive G31 vesicular stomatitis virus mutant in neural and nonneural cells: biological and virological characteristics. 242 95

Fourteen patients with malignant gliomas were entered on a phase II study of 5-fluorouracil 300-370 mg/m2 plus folinic acid 200 mg/m2 x 5 days q4 weeks. To be eligible, patients could not have received more than 1 prior chemotherapy regimen. A single patient with a recurrent oligodendroglioma responded. Toxicity (predominantly stomatitis, diarrhea, and granulocytopenia) was tolerable and was similar to that seen in studies of 5-fluorouracil plus folinic acid in other tumor types. This regimen has minimal activity in recurrent malignant gliomas.
 ...
PMID:A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. 767 88

To determine the efficacy and toxicity of a novel chemotherapeutic approach with topotecan, a camptothecin analog, for progressive or recurring anaplastic oligodendroglioma or mixed oligoastrocytoma.Patients from seven centers with recurrent or progressive disease were treated with topotecan, 1.5 mg/m(2) intravenously (i.v.), 30 min dailyx5 days every 3 weeks. Efficacy and toxicity were assessed clinically and radiologically. The study was planned to accrue up to 30 evaluable patients if there was at least one response among the first 15 patients treated. Sixteen eligible patients entered the study. No response was documented in 14 evaluable patients. Eleven patients had stable disease of a median of 3.8 months and three had progressive disease. Sixteen patients were evaluable for toxicity. The most significant toxic effect was myelosuppression. Grade 3 or 4 granulocytopenia was experienced by 15 of 16 patients and led to dose reduction in nearly half of the cycles delivered. Other adverse effects were fatigue, nausea, stomatitis, alopecia, and vomiting.Topotecan, delivered in the dailyx5 regimen, is relatively well tolerated. We could not demonstrate significant activity among the population studied to justify completing accrual to 30 patients. Topotecan did not demonstrate, with this small sample size, efficacy as a salvage chemotherapy monotherapy after exposure to procarbazine, CCNU and vincristine. Further trials with different agents in this indication are certainly warranted.
 ...
PMID:A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. 1458 16